[breadcrumb_custom]

CRISPR Therapeutics AG Inc. (CRSP) Price Performance: A Technical Analysis Perspective

A mixed performance in the stock price over the year has left investors with either an optimistic or pessimistic outlook, depending on their point of view. The index has shown a price gain of 9.95% this year. Over the last six months, there has been a weaker performance of 29.75%. The price of CRSP fallen by 9.90% during the last 30 days period. For the last 5-days stocks have improved 6.43%.

The stock market performance of CRISPR Therapeutics AG has been very steady. Over the last year, the company’s stock hit its highest at $76.97 on 12/08/23, while the lowest price during the same time frame was $37.55, recorded on 10/23/23.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

52-week price history of CRSP Stock

A stock’s 52-week price history, including the low and high prices, can offer valuable insights into its current standing and future prospects. CRISPR Therapeutics AG’s current trading price is -10.58% away from its 52-week high, while its distance from the 52-week low is 83.30%. The stock’s price range over this timeframe has been between $37.55 and $76.97. The shares of the Healthcare sector company recorded a trading volume of approximately 1.97 million for the day, which was comparatively lower than the average daily volume of 2.8 million over the last three months.

The Connection Between Financial Performance and Market Capitalization

CRISPR Therapeutics AG (CRSP) has experienced a quarterly rise of 17.50% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 5.47B and boasts a workforce of 458 employees.

How Moving Averages and Trading Volume Data Work Together

Based on Barchart.com data, the company’s moving average over the 100-day period was 56.65, with a change in price of +17.55. Similarly, CRISPR Therapeutics AG recorded 2,328,859 in trading volume during the last 100 days, posting a change of +34.22%.

CRSP’s Debt-to-Equity Ratio: A Comprehensive Review

A key metric for assessing a company’s financial well-being and market status is the debt-to-equity (D/E) ratio. This ratio is derived by dividing a company’s total liabilities by its shareholders’ equity, and it demonstrates the level of debt a company uses to support its assets relative to shareholder equity. At the time of writing, the total D/E ratio for CRSP stands at 0.14. Similarly, the long-term debt-to-equity ratio is also 0.13.

CRSP Stock Stochastic Average

CRISPR Therapeutics AG’s raw stochastic average for the past 50 days is currently at 62.59%. This represents a fall from the raw stochastic average of the last 20 days, which was recorded at 94.81%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 89.27% and 82.66%, respectively.

Leave a Reply

Your email address will not be published. Required fields are marked *

On Key

Related Posts